Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P200029/S015

TheraSphere Y-90 Glass Microspheres System

BOSTON SCIENTIFIC CORPORATION · Decision date Oct 13, 2026

MEDTECHLEDGER EXPLANATIONP200029/S015

What did the FDA decide?

The FDA recorded decision OK30 on 2026-10-13 for PMA supplement P200029/S015, submitted by Boston Scientific Corporation under a 30-Day Notice for a process change involving a manufacturer, sterilizer, packager or supplier. The supplement covers the TheraSphere Y-90 Glass Microspheres System, a radionuclide microsphere device classified under product code NAW in radiology.

The recorded scope is narrow: reinstatement of previously approved manufacturing Room 1531 at BWXT Medical Limited for routine manufacture of TheraSphere Yttrium-90 Glass Microspheres. This is a supplement action on an existing approval, not a new approval of the whole system, and the source does not describe clinical performance, patient selection or labeling changes. The source also lists no supporting documents, so the review basis and any conditions tied to the reinstatement remain unknown.

FDA approval order statement

approval for the reinstatement of previously approved manufacturing Room 1531 at BWXT Medical Limited for routine manufacture of TheraSphere Yttrium-90 Glass Microspheres.
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Radiology
Decision date
Oct 13, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P200029/S015
Regulatory pathway
PMA supplement
Product code
NAW
Decision code
OK30
Decision date
Oct 13, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Microspheres radionuclide.

Product code
NAW
FDA device class
3

For the original device and its historical approval scope, see PMA P200029. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P200029/S015 received

    Application receipt date recorded by FDA.

  2. P200029/S015 · FDA decision

    30-Day Notice

Timeline entries are records held by MedtechLedger for P200029. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P200029

Product / regulatory recordCompanyPathwayDecision dateSource
BOSTON SCIENTIFIC CORPORATIONPMA approvalMar 17, 2021FDA

Explore the linked device profile

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Boston Scientific Corporation

Headquarters
Not reported
FDA applicant address
300 Boston Scientific Way, Marborough, MA, 01752

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records